We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics

136 hedge funds and large institutions have $511M invested in Aldeyra Therapeutics in 2021 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 44 increasing their positions, 28 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 21

59% more call options, than puts

Call options by funds: $6.71M | Put options by funds: $4.21M

57% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 28

36% more capital invested

Capital invested by funds: $377M → $511M (+$134M)

26% more funds holding

Funds holding: 108136 (+28)

11.46% more ownership

Funds ownership: 67.13%78.59% (+11%)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

Holders
136
Holders Change
+28
Holders Change %
+25.93%
% of All Funds
2.37%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.07%
New
49
Increased
44
Reduced
28
Closed
21
Calls
$6.71M
Puts
$4.21M
Net Calls
+$2.5M
Net Calls Change
+$3.29M

ALDX Hedge Fund Activity: Q2 2021 in Review

136 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2021, worth a combined $511M — up 36% from $377M a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new ALDX positions and 21 closed out — a net gain of 28 holders — while 44 added to existing stakes and 28 trimmed.

The largest buyer was BlackRock, adding an estimated $26.7M. The largest seller was Avidity Partners Management, cutting an estimated $13.3M.

  • 136 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2021, up from 108 in Q1 2021.
  • Funds reported $511M of Aldeyra Therapeutics stock for Q2 2021, up 36% quarter-over-quarter.
  • 49 funds opened new Aldeyra Therapeutics positions in Q2 2021 and 21 closed out, a net change of +28 holders.
  • The largest Aldeyra Therapeutics buyer in Q2 2021 was BlackRock, an estimated $26.7M added.
  • The largest Aldeyra Therapeutics seller in Q2 2021 was Avidity Partners Management, an estimated $13.3M sold.

Based on aggregated 13F filings for Q2 2021.